ResearcherTel Aviv UniversityActive in the last 2 years

Laurence S. Freedman

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6767-7900; OpenAlex author ID A5002704057. Sources: OpenAlex.

Their work

Papers: 2 (first author 1, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 2

Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 1 paper

Papers 2

Glucagon-Like Peptide-1 Receptor Agonists and Pancreatic Cancer Risk in Patients With Type 2 Diabetes. Last author DOI 10.1001/jamanetworkopen.2023.50408 ↗
Newly diagnosed type 2 diabetes may serve as a potential marker for pancreatic cancer. First author DOI 10.1002/dmrr.3018 ↗

Closest collaborators

The 2 strongest of 2 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Rachel S. Dankner · 2 shared papers, 2018–2024 · strength 0.38
- Paper Glucagon-Like Peptide-1 Receptor Agonists and Pancreatic Cancer Risk in Patients With Type 2 Diabetes. DOI 10.1001/jamanetworkopen.2023.50408 ↗
- Paper Newly diagnosed type 2 diabetes may serve as a potential marker for pancreatic cancer. DOI 10.1002/dmrr.3018 ↗
Lital Keinan‐Boker · 1 shared paper, 2018 · strength 0.11
- Paper Newly diagnosed type 2 diabetes may serve as a potential marker for pancreatic cancer. DOI 10.1002/dmrr.3018 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.